A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Trastuzumab|PROCEDURE: Surgery|RADIATION: Radiotherapy|DRUG: Hormonal Therapy
Sponsor: Hoffmann-La Roche